~~<i id='C3053170C4'><strike id='C3053170C4'><tt id='C3053170C4'><pre id='C3053170C4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：hotspot 2025-09-05 11:31:25 - browse：3382

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Surprise medical billing ban raises prices elsewhere

focus

leisure time

hotspot

entertainment

Wikipedia

leisure time

CardiovasculardoctorsareoptimisticaboutAbbott’snewbelow-kneestentthatdisappearsintothebloodvessel’sw

WSS

FDA warns medical device makers about rise in fabricated data

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Oak Street deal isn't the answer to health care's woes

New CMS data security rules will hurt Medicare, Medicaid research

STAT series 'Denied by AI' wins major journalism prizes

Obamacare plans could cover weight loss drugs

focus

fashion

focus

Hollywood unions extend contract negotiations for actors

Medicare Advantage enrollment hits roughly 33.4 million

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Medical leaders decry Supreme Court decision on affirmative action

Abbott's new stent may help patients with peripheral artery disease

Drug repurposing or repositioning? The language matters

WATCH: Why do our ears pop?

Psychedelics group wrestles with new pharma identity

In 'major milestone,' FDA approves first cell therapy for solid tumors

leisure time

Obamacare plans could cover weight loss drugs

MD Anderson's Padmanee Sharma responds to research credit suit

Oak Street deal isn't the answer to health care's woes

WuXi Biologics execs register to lobby as Congress comes for the company

Weight loss drugs aren’t covered by Obamacare. That may change

The United States must get value

hotspot

entertainment

Wikipedia

leisure time